spacer
home > pmps > spring 2018 > controlled conduct
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Controlled Conduct

PMPS: Can you explain the current prevalence of counterfeiting within the pharmaceutical industry?

Sandra Lee: The WHO estimate 15% of all medicines available worldwide are counterfeit, and, while this decreases to around 1% in the EU, it remains a significant risk to patient safety. As the demand for prescription medicines continues to rise, incentive and opportunity for counterfeiters to interfere with the legitimate supply chain increases.

Pharma manufacturers have been preparing for the adoption of the Falsified Medicines Directive (FMD), which will be enforced in February 2019, as this will provide added security within the supply chain. The additional safeguards of FMD will help protect against counterfeit medicines potentially reaching critically ill patients, such as the recently reported instances of oncology medicines for cancer patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sandra Lee has 35 years’ plus of operational, quality, and project management experience within the commercial and clinical pharma industry, gained through roles at past organisations such as Novartis, Boehringer Ingelheim, Fisher Clinical Services, and now Accord Healthcare. Currently, as the Managing Director of operations at Accord, she leads the manufacturing sites at Barnstaple and Haverhill. Sandra received her BSc in applied chemistry at Brighton Polytechnic, UK, has a post-graduate diploma in industrial pharmaceutical studies, and is also a Chartered Director.
spacer
Sandra Lee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

c-LEcta signs Europe sales and distribution agreement with VWR for c-LEcta’s DENARASE®

• DENARASE® is now available through VWR’s sales channels in Europe • VWR, part of Avantor, is a leading global provider of product and service solutions to laboratory and production customers • Cooperation harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement